Project description
Improved glioblastoma nanomedicine
Glioblastoma multiforme (GBM) is an aggressive and highly invasive brain tumour characterised by poor prognosis and limited treatment options. The blood brain barrier poses a major limitation to the systemic administration of drugs while the suppressive immune microenvironment of the tumour hampers the effectiveness of immunotherapies. The ERC-funded project GLIOMERS is pioneering a localised, immunomodulatory polymeric drug delivery system designed to enhance GBM immunotherapy. Using a microfluidic-assisted method, the research team will develop hybrid nanocarriers combining hyaluronic acid for immunomodulation and poly-L-lysine for brain penetration. These carriers, conjugated with chemotherapeutics, aim to stimulate anti-tumour immunity and achieve local drug distribution. The GLIOMERS novel nanomedicine has the potential to improve T cell-mediated immune responses and therapeutic outcomes for GBM patients.
Objective
Research focusing on cancer immunotherapy has provided little progress toward improved survival rates for patients with glioblastoma (GBM), a poorly immunogenic tumor. Clinical trials for GBM immunotherapy primarily focus on the systemic administration of therapeutics; however, they have shown limited therapeutic success. The blood-brain barrier, the tumor immune microenvironment (TIME), the extracellular matrix, the highly invasive/proliferative nature of GBM, and intra- and inter-patient heterogeneity represent challenges to immunotherapy success. Administering polymer therapeutics as a class of biodegradable nanomedicines for localized treatment − a concept I pioneered − represents a less explored area that may fulfill the potential of GBM immunotherapy while reducing doses and adverse systemic effects.
GLIOMERS aims to design an immunomodulatory brain-penetrating polymeric drug delivery system that will exploit its intrinsic therapeutic effect by synergizing with conjugated chemotherapeutic agent(s) to directly stimulate antitumor immunity. By encompassing different biomaterials properties, hybrid nanocarriers will be developed using a synthetic microfluidic-assisted approach based on chemically stabilized self-assembled hyaluronic acid – as immunomodulator – with complementary poly-L-lysine to support brain penetration. I will capitalize on the properties of this new class of nanocarriers by conjugating chemotherapeutics re-purposed for immunotherapy. This approach will allow not only the local spread of the drug within the GBM, but also an additional rewiring of immunosuppressive TIME with an enhanced T cell-mediated immune response.
GLIOMERS will provide an innovative advance in the design of translational nanomedicines for local brain delivery, contributing to enhanced immunotherapeutic efficacy for GBM treatment.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural scienceschemical sciencespolymer sciences
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- engineering and technologyindustrial biotechnologybiomaterials
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Topic(s)
Funding Scheme
HORIZON-ERC - HORIZON ERC GrantsHost institution
35122 Padova
Italy